IL6 and COVID-19: Tocilizumab, a monoclonal IL-6 antibody, and Janus kinase inhibitors such as baricitinib can be considered in the treatment of patients with moderate disease severity according to the German national guideline for the therapy of COVID-19 [13, 14].